$265.47
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Country

US

CEO

Mr. Joaquin Duato

IPO date

1944

Employees

138,200

ISIN

US4781601046

Key stats

Open

$267.83

Volume

9.13M

Market cap

$643.95B

Prev. close

$267.24

Impl / hst vl

-

Open interest

$0.00

$265.37

Day’s Range

$268.61

$200.91

52W Range

$269.43

Valuation

33
Valuation score
Overvalued
P/E
30.78
P/S
6.72
P/B
7.98
Current ratio
1.03
Debt / Equity
0.57
ROE
26.26%
Gross margin
66.46%
Income growth
2.33%
FCF growth
-73.23

Jun

9

Dividends

The last payment date was Jun 9, 2026

Div. per Share

$1.34

Div. Yield

0.50%

Payout Ratio

-

Div. Growth YoY

3.08%

Analysts estimates

Consensus rating
Buy

The average rating from top 14 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$259.30
The top 27 analysts forecasts that 12-month price may decrease by 2.32%, with a low of $171.70 and a high of $299.25
$171.70
Low
$259.30
Avg
$299.25
High
Current price

Earnings

Q1 ‘26 revenue
$24.06B
Q1 ‘26 net income
$5.24B
Revenue
Net income
Previous EPS
$2.70
Estimate EPS
$2.87
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply